Absci Corporation ABSI Business Segments
| FY'25 | FY'24 | ||
|---|---|---|---|
| R&D by Product | |||
| Drug creation program and platform | $20.35M+23.2% | $16.52M+20.4% | |
| External preclinical and clinical development | $22.4M+140% | $9.34M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Absci Corporation break its business down?
- Absci Corporation (ABSI) reports r&d by product across 2 parts — Drug creation program and platform and External preclinical and clinical development. Each is extracted from the segment footnotes and tracked over time.
- Where does Absci Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Absci Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
